Many research companies working for Hepatitis B and C. Out of them some are claims their medications is almost ready functional cure . So, in this year 2024 there are four anti-viral medications is going for trial phase.
1) Selgantolimod or GS-9688 is a Toll-Like Receptor 8 or TLR8
The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood against that suppresses HBV in vitro.
Tenofovir today exists in two pharmaceutical forms, such as :
Tenofovir disoproxil fumarate (TDF) and the 2) Newer Tenofovir alafenamide (TAF).
Tenofovir alafenamide (TAF) is indicated for adult patients with chronic hepatitis B virus (HBV) infection with compensated liv/er disease at an oral dose of 25 mg per day. This medicine can be prescribed on the recommendation of your doctor only in the forms of oral tablet.
VIR-2218 and VIR-3434 in Combination with PEG-IFN? Doses for Chronic Hepatitis B Virus Infection
VIR-2218 demonstrated an encouraging hepatic safety profile in preclinical and clinical studies as well as dose-dependent HBsAg reductions in patients with chronic HBV infection and a goal of HBV functional cure.
Liver Cirrhosis Network Cohort Study
Liver cirrhosis represents not a single disease, but rather the consequence and major serious outcome of many chronic liver diseases, caused by a wide range of conditions such as by Hepatitis B, C, D, alcohol use disorder, non-alcoholic steatohepatitis, or NASH.
(Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis.
To know more about this video, you should watch our videos in the YouTube channel.
